Metabolic, transcriptomic, and proteomic profiling of relapsed glioblastoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This retrospective observational project analyzes archived tumor specimens from adults with IDH‑wildtype glioblastoma who underwent both initial and repeat surgery at CHU de Bordeaux between 2005 and 2023. Paired primary and recurrent samples will undergo transcriptomic, proteomic, and metabolic profiling to identify molecular changes linked to relapse. Findings will be correlated with relapse‑free and overall survival to search for prognostic markers. No interventions are given; the work uses existing tissue and clinical records.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* age \> 18 years
* surgery for both primary and recurrent glioblastoma between 2005 and 2023 at the CHU de Bordeaux

Exclusion Criteria:

* systemic therapy received for non-glioblastoma tumor

Where it's running

• CHU de Bordeaux - Hôpital Saint-André, Service d'Oncologie Médicale
  Bordeaux, France Recruiting

Study contacts

• Study coordinator: Mathieu LARROQUETTE
• Email: mathieu.larroquette@chu-bordeaux.fr
• Phone: +33 5 56 79 58 08

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• LMP744 (an indenoisoquinolone) for people with recurrent glioblastoma

  This trial will test whether the drug LMP744 can shrink tumors or slow progression in adults whose glioblastoma has returned after prior treatment.

  Recruiting Phase 1/2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07416188

• TTFields with FET-PET–Guided SRS for Recurrent Glioblastoma

  This trial tests whether adding FET-PET-guided stereotactic radiosurgery to TTFields helps adults with recurrent IDH-wildtype glioblastoma live longer than TTFields alone.

  Recruiting Prof. Franciszek Lukaszczyk Memorial Oncology Center · Bydgoszcz · NCT07668869

• ONCOhabitats for surgical and treatment planning in IDH‑wildtype glioblastoma

  This project will try ONCOhabitats MRI software to see if its tumor 'habitat' maps can predict outcomes and help adults with IDH‑wildtype glioblastoma who are having surgery.

  Recruiting at 5 sites Universitat Politècnica de València · Alicante and 4 other locations · NCT07111195

• Roginolisib with venetoclax and rituximab for relapsed or refractory CLL

  This trial will test whether adding roginolisib to the standard venetoclax plus rituximab treatment helps people with relapsed or refractory CLL get deeper and longer remissions.

  Recruiting Phase 1/2 Dana-Farber Cancer Institute · Boston, Massachusetts · NCT06644183

• Investigating a new cancer treatment for relapsed or refractory B-cell malignancies

  This study is testing a new cancer drug called BGB-16673 combined with other treatments to see if it can help people with tough-to-treat B-cell cancers feel better.

  Recruiting at 49 sites Phase 1/2 BeOne Medicines · Phoenix, Arizona and 48 other locations · NCT06634589

• Outpatient teclistamab treatment plan for relapsed or refractory multiple myeloma

  This pilot will try giving teclistamab to adults with relapsed or refractory multiple myeloma in an outpatient clinic to see if it can be delivered safely and practically while measuring effects on caregivers.

  Recruiting Phase 4 University Health Network, Toronto · Toronto, Ontario · NCT06251076

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.